Toxicological screening

Area of Science:

• Pharmacology and Toxicology
• Drug Development
• Regulatory Science

Background:

• Assessing the safety of new chemical entities is a critical step in pharmaceutical research.
• Understanding compound toxicity across different biological systems is essential for predicting human responses.
• Preclinical toxicity studies inform the risk-benefit assessment of investigational products.

Purpose of the Study:

• To review experimental animal models and methodologies employed in preclinical toxicity testing.
• To highlight the importance of in vivo studies in characterizing species-, organ-, and dose-specific toxic effects.
• To emphasize the role of toxicity testing in determining safe starting doses for clinical trials.

Main Methods:

• Review of literature on established animal models for toxicity assessment.
• Discussion of various in vivo exposure methods and their applications.
• Analysis of techniques for identifying toxicological endpoints in experimental animals.

Main Results:

• Experimental animal models provide valuable data on compound toxicity.
• Toxicity testing reveals critical information on dose-response relationships and target organs.
• Established methods allow for the calculation of the No Observed Adverse Effect Level (NOAEL).

Conclusions:

• In vivo toxicity testing in animal models is indispensable for drug development.
• Accurate toxicity data from preclinical studies ensures patient safety during clinical evaluation.
• The NOAEL derived from animal studies is a key parameter for initiating human trials.